Get started
Author

Jessica A. Box

Observed name: Jessica A Box
OpenAlex ID: A5089916031
TER1, the RNA subunit of fission yeast telomerase
2007 · Jessica Leonardi, Jessica A Box, et al. · Nature Structural & Molecular Biology · 127
Spliceosomal cleavage generates the 3′ end of telomerase RNA
2008 · Jessica A. Box, Jeremy T. Bunch, et al. · Nature · 99
Schizosaccharomyces cryophilus sp. nov., a new species of fission yeast
2010 · Rachel M. Helston, Jessica A. Box, et al. · FEMS Yeast Research · 48
A Flexible Template Boundary Element in the RNA Subunit of Fission Yeast Telomerase
2008 · Jessica A. Box, Jeremy T. Bunch, et al. · Journal of Biological Chemistry · 45
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
2015 · Carol J. Fabian, Bruce F. Kimler, et al. · Cancer Prevention Research · 34
PDF
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).
2022 · Mark E. Burkard, Meredith McKean, et al. · Journal of Clinical Oncology · 7
High-dose omega-3 fatty acid supplementation to modulate breast tissue biomarkers in premenopausal women at high risk for development of breast cancer.
2013 · Carol J. Fabian, Bruce F. Kimler, et al. · Journal of Clinical Oncology · 4
A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).
2023 · Andrew H. Ko, Mark Zalupski, et al. · Journal of Clinical Oncology · 2
PDF
Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).
2022 · Timothy Joseph Stuhlmiller, Stacey Cohen, et al. · Journal of Clinical Oncology · 2
Abstract 2693: Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models
2023 · Deborah Knoerzer, Anupama Reddy, et al. · Cancer Research · 1
Abstract 2692: The combination of ulixertinib (ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models
2023 · Deborah Knoerzer, Anupama Reddy, et al. · Cancer Research
Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
2023 · Carol J. Fabian, Bruce F. Kimler, et al.
Data from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
2023 · Carol J. Fabian, Bruce F. Kimler, et al.
Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
2023 · Carol J. Fabian, Bruce F. Kimler, et al.
PDF
Data from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
2023 · Carol J. Fabian, Bruce F. Kimler, et al.
RPFNA cytologic atypia and short-term breast cancer risk in the prevention era.
2014 · Whitney L. Michaels, Carola Maria Zalles, et al. · Journal of Clinical Oncology
Abstract 158: Modulation of breast tissue biomarkers by high dose omega-3 fatty acid supplementation in women at high risk for development of breast cancer.
2013 · Carol J. Fabian, Bruce F. Kimler, et al. · Cancer Research
Works count: 17
Citation count: 369
H-index: 6
I10-index: 5
Year
Topic
Type